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Abstract.  17 
Psoriatic arthritis (PsA) is characterized by chronic inflammation of peripheral joints and axial 18 
skeleton, associated with a strong genetic background. Clinics include enthesitis or dactylitis and 19 
extra-articular involvement as uveitis or inflammatory bowel disease, while treatment options range 20 
from NSAIDs to biologics, targeting TNFalpha or Th17. No serum autoantibody is associated with 21 
PsA, while other biomarkers have been proposed for early diagnosis or to predict treatment 22 
response. To better discuss this area of growing interest we performed a systematic review of the 23 
literature on biomarkers in PsA. Our research retrieved 408 papers, and 38 were included in the 24 
analysis. Based on the available literature, we draw some recommendations for the use of 25 
biomarkers in the management of patients with PsA. 26 
 27 
Keywords: psoriasis, spondyloarthritis, genetics, autoantibodies, personalized medicine, 28 
biologics. 29 
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Introduction.  34 
Psoriatic arthritis (PsA) is a systemic chronic inflammatory disease that involves the synovial tissue 35 
and the entheses, in association with active psoriasis or a personal or family history of the skin 36 
affection. PsA belongs to the broader group of spondyloarthritis (SpA), which also include 37 
ankylosing spondylitis (AS), reactive arthritis, enteropathic arthritis, and undifferentiated 38 
spondyloarthritis 1. All SpA share a strong genetic predisposition, as represented by the association 39 
of AS with the HLA-B*27 allele, but, differently from other rheumatic diseases, there is no female 40 
preponderance or serum specific autoantibodies 2. Within the spectrum of seronegative diseases, 41 
PsA is frequently associated with comorbidities (especially cardiovascular and metabolic disease) 42 
and screening of such complications is not well established 3. The response to treatment in PsA is 43 
currently mostly evaluated with clinimetric indexes derived from other diseases, such as the disease 44 
activity score (DAS28) in rheumatoid arthritis (RA) or the Bath AS disease activity index 45 
(BASDAI), but new composite scores have been developed and validated for PsA, such as 46 
composite psoriatic disease activity index (CPDAI) and others 4-8. The research agenda is currently 47 
moving forward to the identification of biomarkers that could help clinicians to identify subsets of 48 
patients requiring a more targeted therapy or strict monitoring and ideally to diagnose PsA at an 49 
earlier or preclinical stage in patients with skin manifestations 9 but this remains a long-term goal 50 
for which data are limited.  51 
The term biomarker, or biological marker, refers to measurable indicator of a medical state, and was 52 
defined in 1998 by the National Institutes of Health Biomarkers Definition Working Group as a 53 
‘characteristic that is objectively measured and evaluated as an indicator of normal biological 54 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention’ 10. A 55 
classic example of biomarker is a laboratory test that can be used to classify a disease, such as 56 
rheumatoid factor and anti-citrullinated protein antibody (ACPA) in RA 11. In the case of ACPA, 57 
this represents a diagnostic and prognostic factor, and also a treatment response biomarker as 58 
ACPA-positive RA is more aggressive 12. In rheumatic diseases, biomarkers are mainly genetic, 59 
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soluble, cellular, synovial or imaging features 13 and in the case of PsA, where the diagnosis is 60 
exquisitely clinical and inflammatory markers frequently normal, these may be pivotal to 61 
differentiate other conditions, such as fibromyalgia. The identification of biomarkers of PsA is thus 62 
of enormous importance, as nearly 50% of patients will develop erosions in the first 2 years of 63 
disease, and 20% of patients with polyarticular involvement may suffer from a severe form of the 64 
disease, with radiologic evolution over time 14. Moreover, the detection of patients with poor 65 
prognostic factors will help choose which patients need more aggressive treatment with biologic 66 
agents, which are not free of side effects 15 and are burdened by high costs. Aim of this systematic 67 
literature review is to elucidate the state of biomarkers discovery in PsA, and in particular regarding 68 
specific biomarkers for diagnosis, disease activity, therapy response and comorbidities. We propose 69 
our point of view about this key issue in rheumatology clinical practice and foresee the future 70 
research agenda.  71 
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Methods for the systematic literature review. 73 
Our systematic literature review was conducted to identify biomarkers for the diagnosis, prognosis, 74 
therapy, or comorbidities of PsA. Systematic review procedures adopted conform to the Preferred 75 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 16. Structured 76 
literature researches were conducted as of September 2015 in the following databases: The 77 
Cochrane Library, PubMed/MEDLINE and EMBASE. Search terms included the medical subject 78 
headings (MeSH) o Emtree terms for “psoriatic arthritis” and “serum/genetic and synovial 79 
biomarkers”. Titles and abstract were screened to determine if they met the inclusion criteria and if 80 
potentially of interest, two independent reviewers selected relevant abstracts. Articles of particular 81 
interest not being included in the first research were also included independently.  82 
Inclusion criteria. Clinical trials, both interventional and observational, including patients with PsA 83 
and data on biomarkers based on the proposed definition 10 were included.  84 
Exclusion criteria. Articles not concerning PsA, and reviews or editorials, in languages different 85 
from English, if they included children or animals were excluded. The selection process was 86 
performed by two authors, based on titles, abstracts and subsequently full text papers. Figure 1 87 
represents the flowchart of the selection process of this systematic literature review. 88 
Data extraction. The year of publication, geographical area, study design and number of patients 89 
were recorded. Demographic data, such as sex, age, disease duration were also recorded. The 90 
outcome was defined by the identification of a biomarker for diagnosis, disease activity, therapy 91 
response and comorbidities. Articles were divided into four categories whether the investigation 92 
regarded: diagnosis, disease activity, therapy response, or comorbidities. Quality assessment of the 93 
included studies was performed using the Newcastle Ottawa Scale 17. 94 
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Results of the systematic literature review.  96 
The full text analysis included 41 articles, ranging from 1991 to 2015. Most of the studies 97 
investigated biomarkers in term of diagnosis (Table 1), while fewer were dedicated to disease 98 
activity (Table 2) and response to therapy (Table 3) or comorbidities (Table 4).  99 
 100 
Diagnostic Biomarkers 101 
Biomarkers used for diagnosis are particularly helpful in PsA, as no autoantibody has been so far 102 
associated with the disease, and the diagnosis is frequently made in chronic polyarthritis that have a 103 
familiarity for psoriasis but then have different clinical and prognostic features. The results of our 104 
systematic literature review are reported in Table 1 and 16 studies investigating the biomarkers in 105 
diagnosis were included, however the studies were investigating patients with an existing PsA 106 
diagnosis, thus limiting their efficacy.  107 
Genomic factors represent important candidates to differentiate patients with psoriasis more 108 
susceptible to PsA than other but only 4 studies investigated this issue. HLA-B and C molecules are 109 
of interest, and one study reported that HLA-B*27 (p=0.002), B*38 (p=0.04), B*39 (p=0.03), and 110 
C*12 (p=0.005) are potential genetic markers of PsA in patients affected by psoriasis and family 111 
members of probands 18. Another study included analyzed HLA alleles in 678 PsA patients and 688 112 
healthy controls in a case-control design, and demonstrated in a large population than PsA was most 113 
frequently associated with HLA-C*12/B*38, HLA-B*27 and HLA-C*06/B*57 19. Moreover, a 114 
third study included showed that in psoriatic disease there are two HLA alleles that are 115 
predominant: HLA-C*06 in psoriasis and HLA-B*27 in PsA, possibly demonstrating that it 116 
represents a genetic heterogeneous disease 20. The interleukin-13 (IL13) gene polymorphisms have 117 
also been associated with psoriatic disease, and moreover one included study showed that the major 118 
alleles of rs1800925*C, rs20541*G and rs848*C are significantly more represented in PsA 119 
compared to healthy controls and patients with psoriasis 21. Killer-cell immunoglobulin-like 120 
receptor gene polymorphisms have also been associated with PsA, and in particular the alleles 121 
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KIR2DS1 and KIR2DS2. A recent study demonstrated that KIR2DS2 is significantly associated 122 
with PsA (OR 1.34, 95% CI 1.04-1.73, p= 0.024), thus suggesting that the association is likely to be 123 
specific to arthritis 22. Of interest, an included study showed a protective role of the T allele of 124 
VEGF in + 936 for PsA 23. 125 
Serum biomarkers for PsA are being researched both as autoantibodies but also as collagen 126 
fragments and cytokines that may correlate with disease activity and predict therapeutic response. 127 
Among cytokines, serum IL2 and IL10 levels are higher in PsA and may discriminate patients from 128 
healthy subjects and psoriasis 24, 25. Other studies investigated different autoantibodies (anti-129 
agalactosyl IgG, antibodies targeting mutated citrullinated vimentin (anti-MCVs) and ACPA), 130 
showing that these autoantibodies may be positive in PsA, but also in other inflammatory arthritis 131 
(i.e. RA) and identify different subsets of patients with a more severe disease (i.e. polyarticular and 132 
erosive arthritis) 26-28. Other soluble markers, both inflammatory, metabolic and of bone metabolism, 133 
have been associated with PsA and may help differentiate psoriatic patients that may develop PsA 134 
or discriminate PsA from other forms of arthritis, but the results are disparate and may be difficult 135 
to translate into clinical practice 25, 29-33.  136 
Synovial biomarkers derive from the synovial fluid or tissue and are primarily being investigated as 137 
therapy response biomarkers, but are helpful also for diagnostic purposes, in this view protein 138 
oxidative markers have been studies both on sera and synovial fluid of patients with inflammatory 139 
arthritis, namely sulphydryl (SH) and carbonyl (CO) groups. Results show that SH groups sera 140 
levels are higher in PsA than RA and lower than osteoarthritis (OA), while being lower in PsA and 141 
RA synovial fluids compared to osteoarthritis 34. 142 
 143 
Disease activity 144 
Markers of disease activity are important when assessing the disease and to compare therapeutic 145 
response while severity is generally identified as quality of life; studies included are summarized in 146 
Table 2. These biomarkers are mainly derived from sera, as frequent monitoring may be necessary. 147 
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Differently from RA, high sensitivity C reactive protein (hsCRP) does not represent a valid 148 
biomarker for PsA activity as suggested by some studies 35, 36, however others suggest that 149 
correlates better than other biomarkers with disease activity 37. Serum calprotectin has also been 150 
investigated based on data in inflammatory bowel disease, and may better correlate with disease 151 
severity and erosions leading to radiographic changes 35, 37. Erythrocyte sedimentation rate (ESR) 152 
levels in an old study on few subjects was found to be best correlate with disease activity, possibly 153 
performing better that CRP 36. Cellular biomarkers are also of interest especially with regard to 154 
disease progression and erosions, and circulating osteoclast precursors (OCP) represent promising 155 
candidates to assess the presence and severity of PsA. Unfortunately, measuring OCP is time 156 
consuming and expensive, but the expression of molecules such as CD16 may suggest a transitional 157 
state of OCP during osteoclastogenesis and a higher risk of erosions 38. Metabolic markers, as 158 
adiponectin, have also been reported to be associated with PsA severity, and therapy 39. A recent 159 
study investigated the role of programmed death-1 (PD1), a homologue of CD28 and CTLA-4 and 160 
belongs to the immunoglobulin superfamily. The results showed that PD1 inversely correlated with 161 
DAS28, with a very strong correlation with the joint count, while not being associated with CRP 162 
levels and PASI 40. 163 
 164 
Response to treatment 165 
Biomarkers for therapeutic response are very important to identify the specific subsets of patients 166 
that may benefit from a specific therapy and to justify a stricter follow-up of patients using a 167 
therapeutic agent. These biomarkers are usually studied in the serum or synovial fluid, and include 168 
cytokines, collagen degradation proteins or metabolic markers. Table 3 illustrates the studies that 169 
investigated therapeutic response biomarkers in PsA; of these, only 4 investigated synovial fluid 170 
biomarkers for therapeutic response to anti-TNFalpha agents. One study investigated the effect of 171 
intra-articular injections of etanercept on knee arthritis and showed that synovial effusion and 172 
synovial fluid cytokines (IL-1beta, IL-1Ra, IL-6, IL-22) are associated with treatment efficacy 41; 173 
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however, this approach is currently not utilized in clinical practice. Another study randomized 174 
patients with PsA to receive anakinra (directed at IL1beta) or etanercept (soluble TNFalpha 175 
receptor) and took arthroscopic synovial biopsies and MR scans of knee arthritis patients. The 176 
results of the immunohistochemical analysis show that CD3 and CD68 changes are higher in 177 
responders compared to non-responders, and changes in CD3 correlate with DAS28 42. The third 178 
study investigated synovial biopsies by immunohistochemical analysis to determine cell infiltrates 179 
and cytokine and metalloproteinases expression and their results after adalimumab therapy show a 180 
reduction in T-cell infiltrates and MMP-13 expression 43. Cytokine expression has been also 181 
investigated in psoriasis skin lesions, and a study showed a decreased expression of IL20 in the skin 182 
after alefacept treatment, but not in the synovial tissue 44. 183 
Collagen degradation biomarkers have been reported to decrease after anti-TNFalpha therapy, and 184 
may predict better the long-term clinical and radiologic outcomes 45, 46. Other serum biomarkers (i.e. 185 
IL6, VEGF, plasma YKL-40, MMP-3) decrease after anti-TNFalpha therapy in clinical responders 186 
47, 48. Circulating endothelial cells levels, a marker of vascular injury are also decreased after 187 
etanercept therapy 49. Another study investigated adiponectin, but did not show a decrease in serum 188 
levels after anti-TNF treatment 50. Soluble biomarkers have also been reported to predict the 189 
therapeutic response after anti-TNFalpha treatment, MMP-3 levels reduction has been shown to 190 
significantly improve the odds of achieving response, conversely a reduction of COMP levels was 191 
associated with lower odds of achieving response 51. 192 
Of note, using data derived from the GO-REVEAL trial of the TNFalpha inhibitor golimumab, 92 193 
soluble biomarkers were investigated after treatment, and serum levels of different inflammatory 194 
markers were associated with an ACR20 response at week 14, moreover this panel was more 195 
predictive of golimumab response compared to CRP alone 52. 196 
 197 
Clinical extraarticular features.  198 
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Only a few studies investigated biomarkers for the diagnosis and monitoring of comorbidities in 199 
PsA, as illustrated in Table 4. Cardiovascular disease represents the most important comorbidity in 200 
PsA, and a good therapeutic strategy should also take into account the increased cardiovascular risk 201 
of these patients, moreover the identification of patients at higher risk is crucial also to start the best 202 
monitoring and therapy 53. Only two studies included in this systematic review investigated 203 
cardiovascular biomarkers. A study conducted on 11 patients with PsA in Norway studied aortic 204 
stiffness, carotid atherosclerosis and serum calprotectin, showing that calprotectin may represent a 205 
biomarker of aortic stiffness, while anti-TNFalpha treatments improve aortic stiffness and carotid 206 
atherosclerosis 54. Another study showed that PTX-3 levels are higher in patients with inflammatory 207 
arthritis and cardiovascular disease 55.  208 
Osteoporosis represents a major complication of chronic inflammation and frequently occurs in 209 
patients with PsA. BMD levels have been measured in three different studies suggesting that 210 
disease duration negatively correlates with BMD values, and that in general BMD is decreased in 211 
PsA 56, 57. Bone metabolism markers are also correlated with PsA: CTX serum levels is correlated 212 
with disease duration while M-CSF and RANKL correlate with disease severity, i.e. erosions, joint 213 
space narrowing and osteolysis score, moreover TRAIL serum levels are increased in PsA and 214 
correlate with CRP 56-58.  215 
  216 
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Expert commentary.  217 
As the results of our systematic literature review have illustrated, few biomarkers are currently 218 
available to assist clinical decisions in PsA diagnosis and management. With regard to PsA 219 
diagnosis, however all of the studies included analyzed patients with a pre-existing diagnosis and a 220 
selected population overall. Genetic studies may be helpful for detection of such disease, as the 221 
strong familial aggregation supports the evidence of a genetic predisposition. The major loci of 222 
interest have historically been the MHC region and HLA genes, which alleles, especially HLA-223 
C*06, and HLA-B*27, which is carried by about 20-35% of patients 59, B*39 and B*07 that have 224 
been associated to PsA. HLA-B*27 is is also thought to have a pathogenic role in SpA development, 225 
and different theories have been proposed, mostly related to protein misfolding. Moreover, HLA 226 
antigens may also predict different clinical manifestations, as the HLA-B*27 allele is associated 227 
with a higher prevalence of axial disease, while HLA-B*38 and B*39 are linked to peripheral 228 
polyarthritis 60. HLA-B*27 could be also used to discriminate different subsets of PsA, as it has 229 
been reported more frequently in patients with a late development of the skin condition, usually 230 
older than 40 years, but with a short interval between the two conditions, as well as dactylitis and 231 
uveitis 59. Finally, HLA-B*27 is associated with a worse prognosis and disease progression 61. In 232 
this context HLA-B*27 can be of particular help to discriminate patients with psoriasis more prone 233 
to develop PsA, or for early diagnosis in psoriasis when peripheral arthritis or inflammatory back 234 
pain are present. Another HLA antigen of interest is represented by HLA-Cw6*02, which is the 235 
antigen with the strongest association with psoriasis worldwide 62. HLA-Cw6* is a marker for early 236 
development of psoriasis, positive family history and it is positive in nearly 100% of patients with 237 
psoriasis guttata 63. PsA has been also associated with these antigen but with lower magnitude 64. 238 
HLA-Cw6*02 evidence is limited for PsA, however patients carrying this allele may have a better 239 
response to ustekinumab, as suggested by recent studies 65. Serum autoantibodies are a cardinal 240 
feature of most autoimmune diseases and frequently also chronic inflammatory conditions, and 241 
usually precede by years the development of the clinical disease 66. SpA are classically considered 242 
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as seronegative, however, anti-MCVs antibodies have been observed in PsA 27 and RA-specific 243 
serum ACPA 67 are found in as many as 10% of patients with PsA or other inflammatory arthritis. 244 
In fact, ACPA are detected in about 1% of the generally population, more frequently at lower titers 245 
and in smokers 68, 69.  246 
Currently, hsCRP represents the only routine biomarker, helpful for both. However, hsCRP is not 247 
specific to articular inflammation and levels are highly elevated also in infections, particularly 248 
bacterial. Only in one study included in this systematic literature review, hsCRP was found to be 249 
significantly higher in PsA than controls, and the levels are reduced with treatment 30, while 250 
predicting therapeutic response 70. In clinical practice, the determination of hsCRP levels is highly 251 
disappointing, being elevated only in 50% of PsA cases 71, mainly in the elderly 72. High levels of 252 
hsCRP may help however in the discrimination between PsA and psoriasis alone, in which hsCRP 253 
levels are usually within normal range, except in cases of severe skin disease 73-75. Elevated levels 254 
of CRP may also predict radiographic progression 38. On the other hand, clinicians are expected to 255 
consider that the coexisting metabolic conditions, which are frequently seen in PsA may also cause 256 
elevated hsCRP 76. 257 
Finally, with regard of monitoring of comorbidities, clinicians should be aware of the incidence of 258 
such in PsA population and know the most appropriate test to perform when screening. In this view, 259 
we propose the use of serum markers of bone resorption and DEXA for osteoporosis 56-58 as well as 260 
testing for cardiovascular risk factors, knowing that traditional risk scores may underestimate the 261 
real risk.  262 
We are aware that our systematic literature review has limitations: firstly, we decided to include 263 
only PsA and to exclude studies on SpA, that may sometimes incorporate also patients with the 264 
psoriatic forms of axial disease; second, our research question did not include imaging biomarkers, 265 
which have not been clearly identified yet, and we believe that serum and synovial biomarkers may 266 
allow disease stratification and targeted therapies, thus allowing a better management of PsA. 267 
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Five-year view.  269 
Biomarkers represent a major part of the research agenda in all fields of medicine, including 270 
rheumatology, particularly considering the search for tools to personalized medicine 77, 78. In the 271 
case of PsA, the early diagnosis and especially the detection of psoriasis patients with susceptibility 272 
to develop the joint disease is crucial to change the disease course and start effective treatments 273 
soon, while also reducing the risk of developing complications and comorbidities. The Group for 274 
Research and Assessment of Psoriasis and PsA (GRAPPA) has developed and is actively pursuing a 275 
large effort to detect PsA biomarkers. These should fulfill the key features of the OMERACT 276 
(Outcome Measures in Rheumatology Clinical Trials) filter, i.e. truth, discrimination, and feasibility 277 
75, 79-81. Clinical research of GRAPPA is mainly focused on finding a soluble biomarker for 278 
radiographic progression and the analysis of comorbidity biomarkers, specifically cardiovascular 279 
and articular, in a psoriasis inception cohort 82. We herein expect that in the future a soluble 280 
biomarker will be identified and act both as a prognostic factor and as a disease activity 281 
measurement, particularly considering the availability if high-throughput platforms for the analysis 282 
of microRNA, epigenomics, proteomics, and transciptomics 83, 84. However, the identification of a 283 
biomarker is challenging and time consuming 85, and new techniques are approaching to help 284 
finding multiple biomarkers simultaneously, as multiple reaction monitoring mass spectrometry 285 
platform for the measurement of peptides. We encourage the development of shared data and 286 
sample biobanks that may allow the validation of the proposed biomarkers with an accepted study 287 
design 86. This may well be obtained also with the collection of unique populations such as 288 
representative families, naïve patients with different clinical phenotypes, or monozygotic twins 289 
discordant and concordant for psoriasis and PsA 87. 290 
Another important issue in the search for PsA discovery that we expect to be better characterized in 291 
the future is the possibility to stratify PsA patients by their synovial tissue histology and fluid 292 
assessment at diagnosis, thus allowing a more personalized therapeutic approach. The identification 293 
of a proband cytokine in particular patients could help to determine their susceptibility to treatment, 294 
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and, in case of mono or olygoarticular disease, targeted intra-articular injections into the affected 295 
joints, as Fiocco et al demonstrated reduced CD45+ MNC infiltration, and IL-6 and IL-1beta levels 296 
in synovial fluid of after intra-articular etanercept 88. In this view, the possibility of obtaining a 297 
synovial sample at disease diagnosis to characterize the inflammation process could help deciding 298 
the best treatment for every patient.  299 
Finally, more biomarkers are emerging for new biologic agents and small molecules that are 300 
approved or under investigation for PsA and psoriasis 89 and may allow a better allocation of 301 
resources. Most of the studies have been conducted on skin psoriasis and their reproducibility in 302 
PsA is not confirmed. Once again, we submit that the availability of well-established series of 303 
patients and samples at different stages of disease and treatments may make this approach feasible 304 
in the near future. 305 
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Key issues.  307 
1. No serum biomarker for psoriatic arthritis diagnosis has been identified.  308 
2. There are few features that can help discriminate psoriasis patients that will develop 309 
psoriatic arthritis, particularly HLA-B*27.  310 
3. Few biomarkers are reliable disease activity measurements, and hsCRP represent one of 311 
these, even if with many limitations and also being elevated only in half of the patients.  312 
4. Comorbidities are a major concern in psoriatic arthritis, especially cardiovascular and 313 
psychiatric, no biomarker is yet available to identify patients at higher risk.  314 
5. New biomarkers are in the pipeline but the identification and validation is time-consuming 315 
and challenging, new techniques are required to accelerate the process.  316 
6. Synovial biomarkers could be of particular help to stratify patients depending on their 317 
functional status and thus to choose the best therapeutic approach for every patient leading 318 
to personalized medicine.  319 
7. As new molecules for PsA treatment are approaching, research agenda should focus also on 320 
identifying markers for these therapies.  321 
8. Anti-MCVs are present in PsA but are not specific for the disease, as ACPA for RA.  322 
9. HLA Cw6 is of limited use in PsA, different from skin psoriasis. 323 
  324 
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Figure 1. Flowchart of the selection process.  325 
 326 
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Table 1. Articles included: biomarkers of psoriatic arthritis diagnosis.  
Author (Reference) Year Region PsA patients, n (F%) Biomarker investigated Methodology Main results 
Bosè, F. 24 2014 Italy 30 (33.3) IL-2 expression by anti-
CD3 stimulated PBMC 
Comparison of cytokine 
secretion profile of circu- 
lating T cells in patients 
with PsA, patients (30) 
with cutaneous psoriasis 
(21) and blood donors 
(26) 
Increased expression in 
PsA patients compared to 
psoriasis 
Butt, C. 23 2007 Canada 258 (48.5) VEGF, FGF1, FGF2 and 
EGF polymorphisms 
Genotyping of PsA (258) 
and ethnically matched 
controls (154) using 
Sequenom chip-based 
MALDI-TOF mass 
spectrometry platform 
Protective role of the T 
allele VEGF in +936  
Chandran, V. 29 2010 Canada 26 (53.8) IL-12, IL-12p40, IL-17, 
TNFSF14, MMP-3, 
RANKL, OPG, COMP, 
CPII, C2C, C1-2C, 
hsCRP 
Serum analysis in PsA 
(26), psoriasis (26) and 
healthy volunteers (26) 
hsCRP, MMP-3, OPG, 
CPII-C2C ratio 
differentiate patients with 
PsA and psoriasis 
Chandran, V. 19 2013 Canada 678 (57) HLA alleles  DNA genotyping for 
HLA alleles on 678 PsA 
HLA-C*12/B*38, HLA-
B*27 and HLA-
 18 
and healthy controls 
(688)  
C*06/B*57 are more 
frequently associated 
with PsA 
Chandran, V. 22 2014 Canada 678 (57) KIR2D, KIR3D gene 
polymorphisms 
DNA genotyping on 678 
PsA, psoriasis (369) and 
healthy controls (688) 
KIR2DS gene 
polymorphism associated 
with PsA 
Chou, CL. 26 2010 Taiwan 13 (38.5) Anti-agalactosyl IgG 
antibody 
Serum analysis of PsA 
(13), AS (30), RA (22), 
and healthy controls (25) 
Present in inflammatory 
arthritis (including RA) 
Dalmady, S. 27 2013 Hungary 46 (52.1) Antibodies targeting 
mutated citrullinated 
vimentin (anti-MCVs) 
ELISA analysis in PsA 
(46), psoriasis (42) and in 
40 healthy controls  
Higher levels of anti-
MCVs in PsA than 
psoriasis 
Eder, L. 21 2011 Canada 555 (41.5) IL13 gene polymorphism Genotyping of the 
rs20541 and rs848 single 
nucleotide 
polymorphisms of PsA 
(555), psoriasis (342) and 
healthy controls and 
database biobank (217) 
If present increases 
susceptibility for PsA in 
psoriasis patients 
Eder, L. 18 2012 Canada 178 (-) HLA-B and HLA-C  Family-based association 
study on PsA (178), 
psoriasis (30) and first 
degree relatives (561) by 
HLA-B27, HLA-B38, 
HLA-B39 and HLA-C12 
are potential genetic 
markers in patients with 
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genotyping Psa compared to 
psoriasis 
Firuzi, O. 34 2008 Italy 16 (31.2) SH and CO groups in 
sera and synovial fluid 
Sera and synovial fluid 
analysis on PsA (16), RA 
(18) and OA (15) 
SH serum levels were 
higher in PsA than RA 
and lower than OA, SH 
synovial fluid levels were 
lower in PsA and RA 
compared to OA 
Jensen, P. 31 2013 Denmark 42 (57.1) Plasma YKL-40 Level measurement on 
PsA (42), and psoriasis 
(48) 
Plasma YKL-40 is 
increased in PsA, but not 
in psoriasis 
Maejima, H. 28 2010 Japan 15 (33.3) ACPA Serum analysis of PsA 
(15), psoriasis vulgaris 
(15), psoriasis pustolosa 
(3)  
Predictor of server and 
erosive PsA 
Maejima, H. 32 2014 Japan 12 (33.3) Moesin, stress induced 
phosphoprotein-1 
Serum analysis of PsA 
(12), psoriasis (31) and 
healthy controls (31) first 
by two-dimensional 
immunoblotting, then by 
dot blot analysis 
May differetìntiate PsA 
from psoriasis 
Perez-Alamino, R. 33 2014 USA 81 (46.9) ACPA Serum analysis of PsA 
(81) patients  
More severe disease, 
erosive, and polyarticular 
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Ramonda, R. 30 2013 Italy 43 (21) VEGF, MMP-3, PTX, 
hsCRP 
Serum analysis of PsA 
(43) and healthy controls 
(n not known) 
MMP-3, VEGF, hsCRP 
are higher in PsA than in 
controls 
Szodoray, P. 25 2007 Norway 43 (55.8) IL-10, IL-13, IFNalpha, 
EGF, VEGF, CCL3, 
(MIP-1alpha), CCL4 
(MIP1beta), CCLII, FGF, 
G-CSF 
Serum analysis by 
multiplex cytokine assay 
of PsA (43) and healthy 
blood donors (25) 
Discriminated Psa from 
healthy individuals 
Winchester, R. 20 2012 Ireland 359 (-) HLA B and C alleles  Four cohort of patients 
with PsA (359) and 
psoriasis (214), divided 
in discovery and 
validation, population 
derived controls (1000) 
and healthy controls 
(119) 
HLA-C*06 is associated 
with psoriasis and HLA-
B*27 with PsA 
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Table 2. Articles included: biomarkers for psoriatic arthritis disease activity.  
Author Year Region PsA patients, n (W%) Biomarker investigated Methodology Main results 
Chiu, YG. 38 2010 USA 29 (-) CD16 Flow cytometry 
analysis on PBMC and 
monocytes from PsA 
(29), psoriasis (29), RA 
(8) and healthy 
controls (16) 
Intermediate levels of 
CD16 may suggest a 
transitional state of OCP 
during osteoclastogenesis 
and higher erosions 
Eder, L. 39 2013 Canada 203 (39.4) Adiponectin, leptin, 
insulin 
Serum analysis of  PsA 
(203) and psoriasis 
(155) 
Adiponectin associated 
with joint count and 
biologic use 
Hansson, C. 35 2014 Sweden 65 (49.2) Serum calprotectin, 
hsCRP, selected cytokines 
Serum analysis of PsA 
(65) and healthy 
controls (31) 
Calprotectin correlated 
with a more sever disease 
(polyarthritis) 
Helliwell, PS. 36 1991 UK 36 (33.3) Cytidine deaminase 
activity, CRP, ESR and 
histidine 
Serum analysis of PsA 
(36) 
ESR was found to be the 
best correlate for disease 
activity 
Madland, TM. 37 2007 Norway 119 (49.7) Serum calprotectin, 
S100A12, ESR, hsCRP 
Serum analysis of PsA 
(119) 
Calprotectin and S100A12 
are inferior to CRP for 
disease activity but predict 
better radiographic changes 
Peled, M. 40 2015 USA 20 (30) Programmed death-1 Flow cytometry, PD1 inversely correlated 
 22 
ELISA, Western Blot 
and RAP1 activation 
assay analysis of PsA 
(20) and healthy 
controls (15) 
with DAS28, strongly 
correlated with joint count 
but not CRP levels and 
PASI 
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Table 3. Articles included: biomarkers for psoriatic arthritis therapy response.  
Author Year Region PsA patients, n (W%) Biomarker investigated Methodology Main results 
Cauza, E. 45 2006 Austria 9 (44.4) COMP Serum levels 
measurement on PsA (9) 
Short-term infliximab 
therapy decreases COMP 
Chandran, V. 51 2013 Canada 40 (27.5) COMP, hsCRP, MMP-3, 
RANKL, OPG, 
TNFSF14, C2C, C1-2C, 
CPII, CS-846 
Serum levels 
measurements on PsA 
(40) before and after 
anti-TNFalpha treatment 
MMP-3 reduction lively 
to achieve response, 
reduction in COMP 
lower odds of achieving 
response 
De Simone, C. 49 2014 Italy 48 (43.7) Circulating endothelial 
cells levels 
Serum levels 
measurement on PsA 
(48), and healthy subjects 
(50) 
CECs after etanercept 
decreased significantly 
Fiocco, U. 41 2010 Italy 14 (-) Synovial effusion, 
synovial fluid, synovial 
tissue biomarkers in 
knees 
Synovial fluid analysis, 
synovial biopsy with 
immunohistochemistry 
on PsA (14) 
Synovial effusion and 
synovial fluid biomarkers 
are associated with 
efficacy of IA injection 
of etanercept 
Lebre, MC. 44 2012 Netherlands 11 (-) IL-20 in synovial tissue 
and skin 
Immunohistochemistry 
of skin and synovial 
biopsies of PsA (11) and 
RA (10) 
IL-20 decreased in the 
skin of PsA patients after 
alefacept, while it did not 
decrease in synovium 
 24 
Mullan, RH. 46 2007 Ireland 17 (59) C2C, C1,2C, CPII Serum analysis of PsA 
(17), RA (45) 
Short-term changes in 
collagen degradation 
biomarkers following 
biologic therapy predict 
better long-term clinical 
and radiologic outcomes 
Pedersen, SJ. 47 2010 Denmark 17 (-) IL-6, VEGF, YKL-40, 
MMP-3, total aggrecan 
Serum analysis on PsA 
(17), AS (32), and 
healthy volunteers 
These biomarkers 
decrease in anti-TNF 
responders 
Peters, MJ. 50 2010 Netherlands 126 (34.9) Adiponectin Serum levels of PsA 
(126) 
Adiponectin levels did 
not decrease after anti-
TNF treatment 
Pontifex, EK. 42 2011 Ireland 25 (60) Immunohistochemical 
staining of synovial 
biopsies for CD3, CD68, 
FVIII; MRI synovitis 
Immunohistochemistry 
of synovial biopsies of 
PsA (25) 
CD3 and CD68 changes 
were higher in 
responders  
Strober, B. 90 2008 USA 151 (36.4) CRP Retrospective analysis of 
levels in PsA (151) and 
psoriasis (501) 
Etanercept decreased 
CRP levels in PsA 
van Kuijk, AWR. 43 2009 Netherlands 24 (37.5) Synovial cell infiltrate, 
cytokines and metallo-
proteinases expression 
Immunohistochemical 
analysis of synovial 
biopsies of PsA (24) 
T cell infiltration and 
MMP-13 reduction after 
adalimumab therapy 
van Kuijk, AWR. 48 2010 Netherlands 24 (37.5) Serum CPII, PINP, MIA,  MMP-3 decrease tih 
 25 
MMP-3, C2C, COMP, 
OC, NTX-1, ICTP 
adalimumab therapy 
while MIA increase 
Wagner, C. 52 2013 - 100 (-) Biomarker and protein 
profiling (total 92 
markers) 
Serum analysis of PsA 
(100) 
Golimumab is effective 
in modulating markers of 
inflammation, bone 
metabolism, and 
metabolic factors in PsA 
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Table 4. Articles included: biomarkers for psoriatic arthritis comorbidities.  
Author Year Region PsA patients, n (W%) Biomarker investigated Methodology Main results 
Angel, K. 54 2012 Norway 11 (-) Aortic stiffness, carotid 
atherosclerosis, 
calprotectin 
Assessments of aortic 
stiffness (aortic pulse 
wave velocity, aPWV), 
CIMT, and plasma 
calprotectin of PsA 
(11), RA (25) and AS 
(19) 
 
Anti-TNF improved aortic 
stiffness and carotid 
atherosclerosis, 
calprotectin may be a 
marker of aortic stiffness 
Borman, P. 56 2008 Turkey 18 (80) DEXA and bone turnover 
markers 
Serum analysis and 
DEXA of PsA (18) and 
psoriasis (29) 
Disease duration 
negatively correlated with 
BMD values and serum 
CTX levels 
Dalbeth, N. 58 2010 New Zealand 38 (42) Dkk-1, M-CSF, OPG, 
RANKL, DEXA, plain 
joints X-rays 
Serum analysis PsA 
(38), with psoriasis 
(10), and healthy 
controls (12), DEXA 
and X-ray only in PsA 
M-CSF and RANKL 
correlated with erosions, 
joint space narrowing and 
osteolysis score 
Hofbauer, LC. 57 2006 Germany 116 (49.1) Markers of bone turnover, 
DEXA, serum TRAIL, 
OPG 
Serum levels and BMD 
of PsA (116), and 
controls from the 
BMD is decreased in PsA, 
TRAIL serum levels are 
increased and correlate 
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TRAIL cohort (90) with CRP 
Hollan, I. 55 2010 Italy - PTX-3  CAD patients had higher 
levels of PTX-3 
 28 
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APPENDIX 277 
Terms searched for the systematic literature review.  278 
MEDLINE: Mesh terms “psoriatic arthritis” and “serum/genetic and synovial biomarkers” 279 
EMBASE: Emtree “psoriatic arthritis” and “serum/genetic and synovial biomarkers” 280 
COCHRANE: free words search for “psoriatic arthritis” and “serum/genetic and synovial 281 
biomarkers” 282 
Inclusion criteria:  283 
- Clinical trials investigating biomarkers in PsA 284 
- Age of participants >18 285 
- English language  286 
- Full text availability through our bibliotecary services 287 
- Abstract including PsA and serum, genetic and synovial biomarkers. 288 
Exclusion criteria: 289 
- Clinical trials regarding biomarkers in diseases different from PsA 290 
- Children age, as PsA is a rare entity in these patients 291 
- Languages different than English, due to the lack of financial possibilities to traduce the 292 
articles 293 
- Abstract or poster presentations from meetings, as some are incomplete results and are 294 
subsequently reported in future studies 295 
- Duplicates, identified through Endnote 296 
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Data extraction form.  298 
Author: ________________ 299 
Year: ________________ 300 
Geographical region: ________________ 301 
PsA patients (n, F vs.M%): ________________ 302 
Controls: ________________ 303 
Study design: ________________ 304 
Biomarker investigated: ________________ 305 
GENETIC ☐             SYNOVIAL ☐              SERUM ☐ 306 
Main methodology: ________________ 307 
Main results: ________________ 308 
Quality assessment (NOS) * 309 
Selection Criteria  
Adequate case definition  
Representativeness of the cases  
Selection of controls  
Definition of controls  
Comparability  
Controls for diagnosis/age and 
sex 
 
Exposure  
Ascertainment of the exposure  
Method of ascertainment  
Non response rate  
  310 
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Appendix Table 1. Detailed Risk of Bias Results Using the Newcastle–Ottawa Scale for Assessing Quality for Case Control Studies 
 
Study, Year 
(Reference) 
Selection Criteria Comparability Exposure  
 Adequat
e case 
definitio
n 
Representativeness of 
the cases 
Selection 
of controls 
Definition of 
controls 
Controls for 
diagnosis/age and sex 
Ascertainment of the 
exposure 
Method of 
ascertainment 
Non response rate 
Angel, 2012 54 A* B B B  D A* C  
Borman, 2008 56 A* B    A*  A*  
Bosè, 2014 24 A* A* B B  B* E A* C  
Butt, 2007 23 A* A* A* A* B* D A* C   
Cauza, 2006 45 A* B    A*  C    
Chandran, 2010 29 A* A* B A* B* D A* C    
Chandran, 2013 51 A*     D  C    
Chandran, 2013 19 A* B B A* A* D A* C    
Chandran, 2014 9 A* B B A* A* D A* C    
Chiu, 2010 38 A* B B B  D A* C    
Chou, 2010 26 A* A* B A* A* D A* C    
Dalbeth, 2010 58 A* B B A*  D A* C    
Dalmady, 2013 27 A* A* A* A*  D A* C    
De Simone, 2014 49 A* B C B B* D A* C    
Eder, 2011 21 A* A* A* A*  D A* C    
Eder, 2012 18 A* B B B  D A* C    
Eder 2013 39 A* A* B A*  D A* C    
 42 
Fiocco, 2010 41 A* B    D      
Firuzi, 2008 34 A* B C B  D A* C    
Hansson, 2014 35 A* A* C A* B* D A* C    
Helliwell, 1991 36 A* B    D      
Hofbauer, 2006 57 A* B    D      
Hollan, 2010 55 A* A* B A*  D A* C    
Jensen, 2013 31 A* A* B B  D B C    
Lebre, 2012 44 B B B A*  D A* C    
Madland, 2007 37 A* B    D      
Maejima, 2010 28 A* B B A*  D A* C    
Maejima, 2014 32 A* B B A*  A* A* C    
Mullan, 2007 46 A* B B A*  D A* C    
Pedersen, 2010 47 A* B B A*  D A* C    
Peled, 2015 40 A* B B A* B* D A* C    
Perez-Alamino, 2014 33 A* B    D      
Peters, 2010 50 B B B A*  D A* C    
Pontifex, 2011 42 A* B    C A* C    
Ramonda, 2013 30 A* B B A* B* D A* C    
Strober, 2008 90 A* A* B B A* D A* C    
Szodoray, 2007 25 A* A* B A* B* D A* C    
van Kujik, 2009 43 A* A*    D      
van Kujik, 2010 48 A* A*    D      
Wagner, 2013 52 A* A*    D      
Winchester, 2012 20 A* A* B A* B* D A* C    
 
 
